课题基金 / 基金详情

Orexin agonists as novel obesity therapeutics

Orexin agonists as novel obesity therapeutics
食欲素激动剂作为新型肥胖疗法
批准号:
10369478
负责人:
CATHERINE M KOTZ
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-07-01 至 2026-06-30
关键词:
AddressAdultAffectAffinityAgeAgonistAnti-Obesity AgentsAutomobile DrivingBehaviorBehavioralBiological AvailabilityBlood - brain barrier anatomyBody WeightBody Weight decreasedBrainCaloriesCaringChronic DiseaseCognitionDataDesire for foodDevelopmentDietEatingEffectivenessEnergy MetabolismEnvironmentEvaluationExerciseExposure toFeeding behaviorsFutureGeneral PopulationGoalsHealthHealth Care CostsHealthcare SystemsHigh Fat DietHomeHomeostasisHumanHypothalamic structureIndirect CalorimetryIndividualLateralMeasuresMedicalMetabolicMetabolic DiseasesMethodsModelingModerate ExerciseMolecular WeightMorbidity - disease rateMovementMusNarcolepsyNeurodegenerative DisordersNeuronsNeuropeptidesObese MiceObesityOutcomeOverweightPatternPeptide HydrolasesPeptidesPeripheralPharmaceutical PreparationsPharmacotherapyPhysical ExercisePhysical activityPhysiologicalPopulationPreventionPropertyQuality of lifeRadioReceptor ActivationResearchRodentSleepSleep DisordersSleep Wake CycleSleep disturbancesStructureSubconsciousSystemTelemetryTestingTherapeuticThermogenesisTreatment outcomeVertebral columnVeteransVeterans Health AdministrationWeight Gainbaseblood-brain barrier permeabilizationcomorbiditydiet-induced obesityeffective therapyefficacy testingexercise programgood diethealthspanhypocretinimprovedin vivointerestmilitary veterannovelobese personobesity developmentobesity preventionobesity treatmentobesogenicorexin Apre-clinicalpreventreceptorreduced food intakeresearch and developmentscale upside effectsmall moleculesuccesstherapeutic targettooltotal energy expenditureweight maintenancewireless

项目摘要

项目成果

CATHERINE M KOTZ的其他基金

相似基金

相关文献

中文摘要
翻译
超重和肥胖在退伍军人健康管理局(VHA)服务的退伍军人中很常见。 肥胖和与肥胖相关的慢性疾病给我们的医疗保健系统带来了巨大的负担 并降低普通民众和退伍军人的生活质量。随着我们的退伍军人人口老龄化 在接下来的几十年里,这一负担只会增加。除了为数不多的治疗肥胖症的有效药物 在预防方面,肥胖者减肥后长期保持体重没有有效的治疗方法。 以驱动能量消耗的基本机制为治疗目标在以下方面具有更大的红利 改善超重退伍军人的健康,而不是治疗个人的共病 与肥胖有关。肥胖发生的可能机制之一是可获得性减少 下丘脑神经肽食欲素。食欲素神经肽产生于下丘脑的外侧,是 生理功能的关键调节,包括能量平衡、睡眠/清醒稳定和认知。 有缺陷的食欲素系统会导致体重增加,尽管食物摄入量减少,而且完全没有食欲素 神经元导致睡眠障碍发作性睡病,其特征也是体重增加,尽管体重减少 食物摄入量。我们和其他人一直证明食欲素能增强体力活动和精力。 支出,并改善睡眠/醒来模式。尽管这证明了食欲素系统可以 以减肥为目标,由于食欲素缺乏血液,外周给药本身是不可行的。 脑屏障通透性。因此,要实现以食欲素为基础的肥胖症治疗,开发和检测 需要小分子增食欲素激动剂。 这一建议的主要假设是,小分子增食欲素激动剂将阻止 并通过增加能量消耗和改善睡眠/醒来模式来逆转饮食诱导的肥胖。 目标是系统地测试两种小分子增食欲素激动剂在预防和逆转方面的效果。 高脂饮食通过增加能量消耗和改善睡眠/醒来行为而导致肥胖。为此, 我们将让小鼠接受高脂肪饮食,并结合无线无线电遥测使用间接热量测量。 睡眠/觉醒行为分析,以确定外周新的小分子是否激活食欲素受体 分子食欲素激动剂预防和/或逆转肥胖,并改善行为睡眠/醒来模式。这个 目前的目标是产生足够的临床前数据来支持小分子增食欲素激动剂的使用 以防止因暴露在肥胖环境中而导致的不良体重后果。长期的 目标是使增食欲素激动剂的研究和开发成为肥胖和相关疾病的治疗方法 在退伍军人群体中常见的并存现象。
英文摘要
Overweight and obesity are common among Veterans served by the Veterans Health Administration (VHA). Obesity and the chronic diseases associated with obesity place a tremendous burden on our healthcare system and reduce quality of life for the general population as well as for Veterans. As our Veteran population ages over the next decades, this burden will only increase. In addition to few effective pharmacotherapies for obesity prevention, there are no effective therapies for long-term weight maintenance after weight loss in obese subjects. Therapeutically targeting fundamental mechanisms that drive energy expenditure has a larger dividend in terms of improving the health of the overweight Veteran population than would treating individual co-morbidities associated with obesity. One of the possible mechanisms for the development of obesity is decreased availability of the hypothalamic neuropeptide orexin. The orexin neuropeptide, produced in the lateral hypothalamus, are key regulators of physiological functions, including energy homeostasis, sleep/wake stabilization and cognition. A defective orexin system results in weight gain despite reduced food intake, and complete absence of orexin neurons results in the sleep disorder narcolepsy, which is also characterized by weight gain, despite reduced food intake. We and others have consistently demonstrated that orexin enhances physical activity and energy expenditure, and improves sleep/wake patterns. Despite this demonstration that the orexin system can be targeted for weight loss, it’s not feasible to peripherally administer the orexin peptide itself due to its lack of blood- brain barrier permeability. Therefore, to achieve obesity therapies based on orexin, the development and testing of small molecular weight orexin agonists is needed. The overarching hypothesis of this proposal is that small molecular weight agonists for orexin will prevent and reverse diet-induced obesity, through increasing energy expenditure and improving sleep/wake patterns. The goals are to systematically test the efficacy of two small molecule orexin agonists in preventing and reversing high-fat diet-induced obesity by enhancing energy expenditure and improving sleep/wake behavior. To this end, we will expose mice to high-fat diet and use indirect calorimetry in conjunction with wireless radio-telemetric sleep/wake behavioral analyses, to determine if activation of orexin receptors using peripheral novel small molecule orexin agonists prevents and/or reverses obesity, and improves behavioral sleep/wake patterns. The immediate goal is to generate sufficient preclinical data to support use of small molecular-weight orexin agonists to prevent adverse body weight outcomes associated with exposure to obesogenic environments. The long-term goal is to enable research and development of orexin agonists as therapies for obesity and associated comorbidities commonly observed in the Veteran population.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Reducing the post weight-loss energy expenditure gap with orexin agonists
  • 批准号:
    10745184
  • 项目类别:
  • 资助金额:
    $73.1万
  • 财政年份:
    2023
  • 负责人:
    CATHERINE M KOTZ
  • 依托单位:
Orexin agonists as novel obesity therapeutics
  • 批准号:
    10655285
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2022
  • 负责人:
    CATHERINE M KOTZ
  • 依托单位:
Fisetin as a treatment for community-acquired pathogen susceptibility during aging, obesity and neurodegenerative diseases
  • 批准号:
    10610378
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2022
  • 负责人:
    CATHERINE M KOTZ
  • 依托单位:
Fisetin as a treatment for community-acquired pathogen susceptibility during aging, obesity and neurodegenerative diseases
  • 批准号:
    10425193
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2022
  • 负责人:
    CATHERINE M KOTZ
  • 依托单位:
海外基金